Michalis Kostapanos

Consultant Physician / Affiliated Assistant Professor

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (15)

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (8)

Matilda Florentin

University of Ioannina

GREECE

View details

Ian B. Wilkinson

Cambridge University Hospitals NHS Foundation Trust

UNITED KINGDOM

View details

Simon Bond

UNITED KINGDOM

View details

James Goodman

Cambridge University Hospitals NHS Foundation Trust

UNITED KINGDOM

View details

Joseph Cheriyan

UNITED KINGDOM

View details

Tian Zhao

Clinical Lecturer in Cardiovascular Medicine

University of Cambridge

UNITED KINGDOM

View details

Arthur Pratt

Clinical Senior Lecturer

Newcastle University

UNITED KINGDOM

View details

Aris P. Agouridis

European University Cyprus

CYPRUS

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Michalis Kostapanos

Research Interests

Explore related searches

Contact this professor

Articles (15)

The effect of rosuvastatin alone or in combination with fenofibrate or omega-3 fatty acids on lipoprotein(a) levels in patients with mixed hyperlipidemia.

Statins.

Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial.

Regulatory T-Cell Response to Low-Dose Interleukin-2 in Ischemic Heart Disease

Early Investigational and Experimental Therapeutics for the Treatment of Hypertriglyceridemia

Is there a role of lipid-lowering therapies in the management of fatty liver disease?

Lipoprotein (a) as a treatment target for cardiovascular disease prevention and related therapeutic strategies: a critical overview.

Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment.

Investigating the Lowest Threshold of Vascular Benefits from LDL Cholesterol Lowering with a PCSK9 mAb Inhibitor (Alirocumab) in Patients with Stable Cardiovascular Disease (INTENSITY-HIGH): protocol and study rationale for a randomised, open label, parallel group, mechanistic study

Comparison of the Pharmacokinetics of RIPK1 Inhibitor GSK2982772 in Healthy Western and Japanese Subjects

Baricitinib set to join the Covid-19 therapeutic arsenal?

Advanced imaging for quantification of abnormalities in the salivary glands of patients with primary Sjögren's syndrome.

Recent developments in pharmacotherapy for hypertriglyceridemia: what’s the current state of the art?

Repurposed immunomodulatory drugs for Covid-19 in pre-ICu patients - mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 - Repurposed Drugs (TACTIC-R): A structured summary of a study protocol for a randomised controlled trial

muLTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19-Experimental drugs and mechanisms (TACTIC-E): A structured summary of a study protocol for a randomized controlled trial

Collaborators (8)

Matilda Florentin

Ian B. Wilkinson

Simon Bond

James Goodman

Joseph Cheriyan

Tian Zhao

Arthur Pratt

Aris P. Agouridis

Make your next move.